Clinical trial
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)
The objective is to compare the efficacy and the safety of masitinib at 3 mg/kg/day or 4.5 mg/kg/day versus placebo in the treatment of patients with severe COPD.
| Category | Value |
|---|---|
| Study start date | 2013-06-24 |